Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 20, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 900,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,281 pence per share; lowest price paid was 1,269 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 499,174,284 shares in Treasury.
- Treasury Percentage: Represents 8.84% of total issued share capital and 9.70% of total voting rights.
- Shares in Issue: 5,146,191,413 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 900,000 repurchased shares. This transaction increased the proportion of Treasury shares held by the Company to 8.84% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,146,191,413) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.70%).
- Review the remaining authority for share repurchases under the mandate granted at the May 5, 2011 Annual General Meeting.